Author: Tang Jordan Ghosh Arun Hong Lin Koelsch Gerald Turner Robert Chang Wanpin
Publisher: Humana Press, Inc
ISSN: 0895-8696
Source: Journal of Molecular Neuroscience, Vol.20, Iss.3, 2003-08, pp. : 299-304
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The discovery that β-secretase is a membrane-anchored aspartic protease memapsin 2 has stimulated much interest in the design and testing of its inhibitors for the treatment of Alzheimer’s disease. This article discusses the strategy for the development of such inhibitor drugs. Enzymology and structural determination tools have permitted the design of memapsin 2 inhibitors with high potency and in a size range possible for penetration of the blood-brain barrier. Transgenic Alzheimer’s mice have been used to show that when memapsin 2 inhibitors are transported to the brain, they effectively reduce the production of amyloid β. Although development of a clinical candidate of memapsin 2 inhibitor drug remains a very challenging undertaking, the progress so far lends some optimism for future prospects.
Related content
Recent Developments on the Studies of Human Memapsin 2 (&bgr;-Secretase)
Current Alzheimer Research, Vol. 2, Iss. 2, 2005-04 ,pp. :
Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality
Current Alzheimer Research, Vol. 4, Iss. 4, 2007-09 ,pp. :
Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development
Current Alzheimer Research, Vol. 5, Iss. 2, 2008-04 ,pp. :
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
By Hussain I. Powell D. Howlett D.R. Tew D.G. Meek T.D. Chapman C. Gloger I.S. Murphy K.E. Southan C.D. Ryan D.M. Smith T.S. Simmons D.L. Walsh F.S. Dingwall C. Christie G.
Molecular and Cellular Neuroscience, Vol. 14, Iss. 6, 1999-12 ,pp. :